> Detailanzeige

Gorlick, Richard G.; Abramson, David H.; Sowers, Rebecca; Mazza, Beth Anne; Dunkel, Ira J.

Impairments in antifolate transport are common in retinoblastoma tumor samples

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Impairments in antifolate transport are common in retinoblastoma tumor samples
  • Beteiligte: Gorlick, Richard G.; Abramson, David H.; Sowers, Rebecca; Mazza, Beth Anne; Dunkel, Ira J.
  • Erschienen: Wiley, 2008
  • Erschienen in: Pediatric Blood & Cancer
  • Sprache: Englisch
  • DOI: 10.1002/pbc.21266
  • ISSN: 1545-5009; 1545-5017
  • Schlagwörter: Oncology ; Hematology ; Pediatrics, Perinatology and Child Health
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Many patients with retinoblastoma have a genetic predisposition to cancer and external beam radiation therapy and alkylating agent chemotherapy may increase their risk of secondary malignancy. Identification of effective chemotherapy agents for retinoblastoma that are not associated with an elevated risk of secondary malignancy would be beneficial.</jats:p></jats:sec><jats:sec><jats:title>Procedure</jats:title><jats:p>Twenty‐six specimens of fresh retinoblastoma tumor cells were studied in vitro with a PT430 competitive displacement assay. Differential displacement of the PT430 by methotrexate and not trimetrexate was considered indicative of a defect in reduced folate carrier (RFC)‐mediated transport. Elevations in the accumulation of PT430 were considered indicative of dihydrofolate reductase (DHFR) amplification.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In 9 of the 26 (35%) samples, displacement by methotrexate was less than half the displacement by trimetrexate indicative of a defect in the RFC. In 5 of the 26 (19%) samples, trimetrexate did not displace the PT430. In 7 of 26 (27%) samples, the peak PT430 accumulation was suggestive of DHFR overexpression. Overall 9 of 26 (35%) samples had no evidence of a transport defect or DHFR overexpression and would be anticipated to be potentially sensitive to methotrexate. In 15 of the 26 (58%), no defects existed in trimetrexate displacement or DHFR overexpression and would be anticipated to be potentially sensitive to trimetrexate.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>These results would support consideration of a phase II study to determine the effectiveness of trimetrexate for recurrent intra‐ocular retinoblastoma. Pediatr Blood Cancer 2008;50:573–576. © 2007 Wiley‐Liss, Inc.</jats:p></jats:sec>